Obesity Medicine

Latest News

Once-Monthly Maridebart Cafraglutide Produces Up to 20% Weight Loss in Phase 2 Trial
Once-Monthly Maridebart Cafraglutide Produces Up to 20% Weight Loss in Phase 2 Trial

June 26th 2025

ADA 2025: Once-monthly dosing led to significant weight loss in adults with obesity, with or without type 2 diabetes, reported researchers.

Viking Advances GLP-1/GIP Agonist VK2735 into Late Stage Clinical Program for Obesity   / image credit ©Viking Therapeutics
Viking Advances GLP-1/GIP Agonist VK2735 into Late Stage Clinical Program for Obesity

June 26th 2025

Mifepristone Reduced HbA1c, Body Weight in Adults with Hypercortisolism and Inadequately Controlled T2D: CATALYST Trial Treatment Phase
Mifepristone Reduced HbA1c, Body Weight in Adults with Hypercortisolism and Inadequately Controlled T2D: CATALYST Trial Treatment Phase

June 24th 2025

 Bimagrumab + Semaglutide Highly Effective for Loss of Fat, Preservation of Muscle in Phase 2b BELIEVE Trial / image credit American Diabetes Association
Bimagrumab + Semaglutide Highly Effective for Loss of Fat, Preservation of Muscle in Phase 2b BELIEVE Trial

June 24th 2025

Orforglipron, an Investigational Oral GLP-1, Cuts HbA1c and Body Weight in People With T2D
Orforglipron, an Investigational Oral GLP-1, Cuts HbA1c and Body Weight in People With T2D

June 23rd 2025

More News

© 2025 MJH Life Sciences

All rights reserved.